Novo Nordisk– tag –
-
The Rise of Oral GLP-1 Receptor Agonists: Transforming Diabetes and Obesity Treatment Convenience from Injections to Pills
Pharmacy Times USA Overview The advent of oral GLP-1 receptor agonists (GLP-1RAs) is fundamentally transforming drug administration in diabetes and obesity treatment. Oral formulations are rapidly gaining traction in the previously injec... -
GLP-1 Receptor Agonists Expand Therapeutic Scope to MASH: Novo Nordisk’s Wegovy First FDA-Approved for MASH, Eli Lilly’s Oral Foundayo Launched
Drug Discovery Trends USA Overview The therapeutic scope of GLP-1 receptor agonists has expanded beyond diabetes and obesity to include cardiovascular risk, obstructive sleep apnea, chronic kidney disease, and by 2025, MASH (Metabolic Dy... -
AI Significantly Reduces Drug Discovery Space: De Novo Protein Design and Bruker’s Data Platform Accelerate Innovation
Temple 8 Unknown Overview AI models are drastically reducing the biological exploration space in drug discovery by screening billions of virtual molecules in seconds, predicting binding affinities, and optimizing pharmacokinetic properti... -
McKinsey Report: Generative AI and Foundation Models Revolutionize Biopharma R&D Workflow, Accelerating Molecular Design and Antibody Engineering
McKinsey Unknown Overview A McKinsey report highlights that generative AI and foundation models are revolutionizing biopharma R&D workflows. These AI models design novel molecular structures, experimental hypotheses, and synthetic pa... -
Cultivated Meat Institute Envisions Sustainable Future with >99% Media Cost Reduction and Significant Bioreactor Capacity Expansion
Alt Protein Planet USA Overview Dr. Elliot Swartz of the Cultivated Meat Institute reported that the cultivated meat industry has achieved over 99% reduction in media costs and significantly expanded bioreactor capacity over the past dec... -
Novo Nordisk’s Zenagamutide: Dual GLP-1/Amylin Agonist Delivers Significant Metabolic Gains in Type 2 Diabetes
Healio デンマーク Overview Novo Nordisk's novel unimolecular GLP-1/amylin receptor agonist, zenagamutide, has demonstrated significant reductions in HbA1c and body weight in adults with type 2 diabetes during its Phase 2 clinical trial. ... -
Novo Nordisk’s Oral Wegovy Approved in UK, Becoming Europe’s First Oral GLP-1 Obesity Treatment
Clinical Research News UK Overview Novo Nordisk's oral GLP-1 receptor agonist, Wegovy (semaglutide tablet), has received approval in the UK, marking its entry as the first oral obesity medication in Europe. This approval is expected to s... -
Biologically-Driven Generative Chemistry: Advanced Deep Generative Models for De Novo Drug Design
ChemRxiv International Overview A new preprint study reviews biologically-driven generative chemistry, emphasizing deep generative models for novel molecular design. These models now integrate diverse biological data, including bioassays... -
Isomorphic Labs Secures $2.1B Series B Funding to Scale AI Drug Discovery Platform ‘IsoDDE’
IntuitionLabs UK Overview Isomorphic Labs, a Google DeepMind spin-off, has successfully raised $2.1 billion in Series B funding to globally expand its AI-driven drug discovery platform, 'IsoDDE,' and advance multiple drug programs. Built... -
Denmark Fortifies Biomanufacturing Leadership with $239M AGC Biologics Investment
GeneOnline デンマーク Overview Denmark is rapidly consolidating its position as a global biomanufacturing powerhouse, attracting substantial investment in its advanced infrastructure. AGC Biologics has committed $239 million to significa...
